Allergan Aesthetics, an AbbVie company, has announced that the FDA has approved BOTOX® Cosmetic for the temporary enhancement of moderate to severe vertical bands connecting the jaw and neck, known as platysma bands, in adults.
This development marks BOTOX® Cosmetic as the first and only product authorized for four aesthetic areas: forehead lines, frown lines, crow's feet, and now platysma bands.
The platysma is a thin muscle that spans the neck and extends over the lower face. When contracted, it can result in visible bands on the neck, thereby contributing to a less defined jawline.
The treatment with BOTOX® Cosmetic operates beneath the skin's surface to temporarily diminish the muscle activity, thereby improving the appearance of the neck and jaw connection, as detailed by the company.
By injecting along the jawline and the vertical bands linking the jaw and neck with one of the FDA-approved dosages of BOTOX® Cosmetic, according to severity—26, 31, or 36 units—the product temporarily alleviates underlying muscle activity.
"With the approval of BOTOX® Cosmetic for treating platysma bands, which includes specific injection patterns and dosages, I can now confidently present my patients with a treatment option that aligns with their desired outcomes," stated Dr. Terrence Keaney, a board-certified dermatologist and key clinical trial investigator.
